Prison ADHD drug trial aims to cut recidivism

NCT ID NCT05842330

Recruiting now Disease control Sponsor: Stéphanie Baggio Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a common ADHD medication (OROS-methylphenidate) can help prisoners with ADHD manage their symptoms and reduce problem behaviors. About 150 adults in French prisons will receive either the drug or a placebo for several months. Researchers will track changes in ADHD severity and incidents like fights or self-harm.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADHD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

attention deficit hyperactivity disorder, inattentive type attention deficit-hyperactivity disorder Recidivism Treatment Adherence and Compliance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADHD

Contacts and locations

Locations

Geneva University Hospitals
RECRUITING

Geneva, Canton of Geneva, 1211, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.